Lucis raised a $20 million Series A this month, which is unremarkable until you notice the company was founded in 2025 and raised its $8 million seed only four months earlier. That’s not a funding round, that’s a company being chased. Singular led, with General Catalyst and Y Combinator following, bringing the total to $28 million for a company barely a year old.
The product is preventive health, a category with a graveyard’s worth of wellness-adjacent flops behind it. Lucis’s version is more clinical than most: it analyses more than 110 blood biomarkers across metabolic health, hormones, cardiovascular risk, inflammation and nutrient levels, feeds the results into an AI companion app, and, crucially, has physicians review the guidance before it reaches you. The pitch from co-founder Maxime Berthelot is that “the science is already there; what’s missing is a system designed to act before symptoms appear.”
At first test, 99.9% of Lucis users had at least one biomarker outside the optimal range, usually without knowing it. Either everyone is quietly unwell, or “optimal” is a marketing range. Probably a bit of both, and either way it sells retests.
The traction data is the kind that makes investors move fast. Among users who did a six-month follow-up, 75% improved at least three biomarkers without medication, and more than 80% chose to retest, which, in a category defined by people trying something once and forgetting it, is the metric that matters. Over 10,000 users across France, the UK, Ireland and Portugal, more than a million biomarker tests run, lab partnerships with Eurofins and Randox.
The skeptic’s note writes itself: a platform that tells 99.9% of users something is “off” and then sells them the retest has an incentive structure worth watching, and “prevention” is easier to sell than to prove over a decade. But the European framing is genuinely sharp, Berthelot wants prevention to be “the default, rather than a privilege”, and a Paris company going from zero to a chased Series A in a year, with Spain, Germany and Italy next, is exactly the kind of compounding this continent keeps producing.